PHVS stock news · Pharvaris N.V.

Stories about Pharvaris N.V. (PHVS) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for PHVS

Follow Pharvaris N.V. (PHVS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Free on the App Store and Google Play, or on the web.

Oct 23, 2026, 2:18 PM ET · Opinion
An analyst thinks Pharvaris is a good choice now that worries about its drug are lessening.
Good for PHVS
Pharvaris received an analyst upgrade after doctors praised its prevention-trial results. Reviews are pending and rivals remain, but the report reads as favorable for the company.
Sep 9, 2026, 9:12 AM ET · Opinion
Imax could jump over 23%! Check out 10 expert predictions for Wednesday.
Good for PHVS
Wedbush raised Pharvaris's price target from $42 to $50 and kept an Outperform rating, which is a favorable analyst view for Pharvaris.
Sep 8, 2026, 10:20 AM ET · Market
On Tuesday, Roivant Sciences, Pharvaris, IonQ, and other major stocks saw their prices go up.
Good for PHVS
Pharvaris announced statistically significant, clinically meaningful Phase 3 topline results, and its stock jumped after the release.